The diagnostic standard for hematological malignancies includes conventional chromosome analysis and fluorescence in situ hydridization (FISH). With these methods somatic alterations of the DNA can be identified and the karyotype can be established. Additionally, NGS-based analysis is used for the identification of specific mutations.<\/p>\n\n\n\n
The determination of the karyotype and gene mutational analyses are necessary for the diagnosis and classification of hematologiocal neoplasms. Moreover, these diagnostic tools have prognostic and therapeutic significance, which means they can be utilized to support the selection of risk-adapted treatments and for patient follow-ups (early relapse detection).<\/p>\n\n\n\n
\u200bIn addition to chromosome analysis, FISH analyses are used to answer specific questions. The FISH technique allows the ascertainment of structural chromosomal changes and the examination of cells in a non-dividing state (interphase nuclei). In many cases, FISH can be used to verify the treatment response.<\/p>\n\n\n\n
\u200bNext generation sequencing (NGS) based gene panel diagnostics facilitates the simultaneous sequencing of many genes. Our current panel includes 179 genes with relevance in myeloid and lymphoid neoplasms. Based on the WHO, various clinical practice guidelines and the current state of knowledge, we will compile appropriate subpanels for each specific entity and will update and optimize these subpanels continuously. Additionally, based on our 179 gene panel, we can create customized subpanels according to the specifications of our clients.
The processing time for examinations of hematologic neoplasms is approx. 14 days.
<\/p>\n\n\n\n
Sample material<\/strong><\/p>\n\n\n\n \u200bFor more information, please visit the Preanalytics page or download our information guide as PDF under the following link:<\/p>\n\n\n\n \u200b<\/p>\n\n\n\n\n